Note: Ingredients listed on restricted chemical lists
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
0.3%
EC/CAS
7647-01-0
Name of the chemical
Hydrochloric acid
Concentration
0.8%
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
96.9%
General Information
Revision date
2016-09-09
Product name
Axumin
Product Synonyms
Fluciclovine F 18 injection
Manufacturer Name
Manufactured for Blue Earth Diagnostics Limited by
Emergency telephone
1-800-255-3924
Icons in SDS
Company Information
company name
PETNET Solutions, Inc.
Section 2
SECTION 2: Hazards identification
Emergency Overview: Read package insert prior to use. Axumin™ is a diagnostic radiopharmaceutical for intravenous use only. It emits radiation and must be handled with appropriate safety measures to minimize radiation exposure to clinical personnel and patients. Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose training and experience has been approved by the appropriate government agency authorized to license the use of radionuclides.
Other physicochemical hazards
Ratings (0 = minimal, 1 = slight, 2 = moderate, 3 = serious, 4 = severe) NFPA: Health 1 Flammability 0 Stability 0 HMIS: Health 1 Flammability 0 Stability 0
Potential health effects
Inhalation: Axumin™ does not easily become airborne. Not expected to be a health hazard via inhalation. Ingestion: May cause asymptomatic physiological uptake by specific target organs or tissues. Skin Contact: Not considered an acute health hazard. Eye Contact: May cause eye irritation on contact. Chronic Exposure: Data on biological effects of ionizing radiation are based on exposures much higher than those permitted occupationally. No effects are expected from exposures received as a result of normal use.
